Held during the Society of Gynecologic Oncologists (SGO)
2004 Annual Meeting on Women’s Cancer

For reference only; not available for CME credit

Download Slides (36MB, requires PowerPoint)

The following information was taken from the original meeting...

Target Audience:
This activity is designed for healthcare providers interested in the latest research on proteomic techniques developed for cancer diagnosis and therapeutics.

Activity Goal
The goal of this activity is to consider current research in the detection of early stage ovarian cancer and the clinical impact these new diagnostics may have on ovarian cancer patients.

top

Learning Objectives
After completing this course, the participant should be able to:

• List the current methods available for ovarian cancer detection
  
• Summarize the current trends in the diagnostics for ovarian cancer detection
  
• Understand the clinical implications of proteomics
  
• Describe the possible implications of new advances in diagnostics for patients with ovarian cancer
  

top

This independent CME activity is supported by an educational grant from Quest Diagnostics Incorporated.

top


Chair

David A. Fishman, MD
Director, National Ovarian Cancer Early Detection Program
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine
Northwestern University
Chicago, IL

Kevin Rosenblatt, MD, PhD
Assistant Professor
Associate Director, Division of Translational Pathology
Department of Pathology
University of Texas Southwestern
Dallas, Texas

Gordon R. Whiteley, PhD, RM (CCM)
Director, Clinical Proteomics Reference Laboratory
SAIC-Frederick, Inc.
National Cancer Institute at Frederick
Gaithersburg, MD

top